Flow cytometric evaluation of biomarkers

临床定量流式细胞术是一种新技术，它利用专门的抗体染色技术和荧光标准来定量检测样本中不同细胞群体的抗原表达。流式细胞术单元使用这项技术来量化接受各种抗原导向治疗(例如治疗性抗体、CAR T细胞治疗)的患者的肿瘤细胞抗原表达。流式细胞仪分析快速且非常准确。这提高了NCI研究人员监测抗原表达减少或增加的能力，以及将与肿瘤细胞结合的抗体与治疗反应进行比较。在治疗后立即定量荧光抗体结合也可以精确地确定非标记治疗性抗体的抗原位置的饱和度。在治疗前、治疗中和治疗后对抗原进行定量可能有助于深入了解被新型治疗药物破坏的途径。因此，抗原定量对于NCI研究人员来说是一个巨大的资源，这是其他机构无法获得的。流式细胞仪检测也被用来评估在NCI接受嵌合抗原受体(CAR)T细胞治疗的患者。它在评估嵌合抗原受体(CAR)T细胞治疗的反应中起着至关重要的作用，它通过定量检测治疗性CAR T细胞在患者体内的扩增，同时监测肿瘤细胞的减少。此外，流式细胞术单位还继续支持CCR艾滋病毒和艾滋病恶性病科正在进行的研究，包括开发新的生物标记物分析，如LANA1流式细胞仪，用于评估与HHV8相关的B细胞淋巴瘤或淋巴增生性疾病，以及评估潜在的治疗靶点，如CD38，用于治疗原发渗出性淋巴瘤。

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antigen expression by different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antigen expression in patients undergoing various antigen directed therapies (e.g. therapeutic antibody, CAR T-cell therapy). The flow cytometric assays are rapid and very precise. This improves the ability of NCI investigators to monitor decrease or increase in antigen expression, as well as compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. Quantitation of antigens prior to, during and post therapy may provide insight into pathways disrupted by novel therapeutic agents. Antigen Quantitation is therefore a tremendous resource for NCI investigators that is not available at other institutions. Flow cytometric testing is also utilized to evaluate patients receiving chimeric antigen receptor (CAR) T cell therapy at NCI. It plays a vital role in assessing response to chimeric antigen receptor (CAR) T cell therapy by quantitating expansion of the therapeutic CAR T cells in the patient while at the same time monitoring the decrease in neoplastic cells. Additionally, the Flow Cytometry Unit also continues to support ongoing research in the CCR HIV and AIDS Malignancy Branch, including development of new biomarker assay, such as LANA1 flow cytometric assay, for evaluation of HHV8-associated B-cell lymphoma or lymphoproliferative disorders, and evaluation of potential therapeutic target, such as CD38, for primary effusion lymphoma.